THERAPEUTIC PLATFORM

Sequence Library

The ability to effectively select appropriate disease targets plays a critical role in the development and optimization of RNAi therapeutics.

KEY SEQUENCE FEATURES
  • Double Blunt-Ended
  • Versatile Lengths Including 19, 21, 23 and 25 Base-Pairs
  • High Potency
  • Optimized Molecular Structure
  • Cross-Species Homology
          

To maximize target selection success, Silence weighs a number of critical considerations including the role the target plays in disease modification, the cell type in which the target is expressed and other IP-related considerations in developing a therapeutic against the target.

Through diligent scientific research based on both bioinformatics algorithms and unique know-how, Silence has compiled a library of proprietary siRNA sequences against more than 50 high-value disease targets.  The company has built a strong intellectual property position around its sequence library, including protection for certain specific disease targets.